Lisata regains Nasdaq minimum bid price compliance; delisting risk removed

LISATA THERAPEUTICS, INC.

Received Nasdaq deficiency letter on Feb 18, 2022 for bid price below $1.00.
Granted initial 180-day period ending Aug 17, 2022, then second period to Feb 13, 2023.
On Sept 29, 2022, notified compliance regained after 10 consecutive days at $1.00+.
Nasdaq confirmed the matter is now closed.
Stock ticker LSTA remains listed on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.